These results shed new light on the mechanisms involved in lung tumorigenesis and lay the foundations to potentially develop more effective therapeutic strategies for both PDGFR- and KRAS-driven NSCLC. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.